Is Trump to blame for delayed drug launches in Europe
WhatUS trade policies under former President Trump have been criticized for potentially delaying the launch of certain drugs in Europe due to increased regulatory hurdles and trade tensions.
WhyThe European Medicines Agency (EMA) has reported a significant increase in the time it takes for new drugs to receive approval, partly attributed to the complex and often contentious process of navigating US-EU trade agreements.
SignalThis trend may signal a broader shift in the global pharmaceutical landscape, where trade policies and regulatory frameworks are increasingly intertwined, posing challenges for companies seeking to bring innovative treatments to market.
TargetPharmaceutical companies are likely to target regulatory reforms and diplomatic efforts to mitigate the impact of trade tensions on drug launches, potentially leading to increased collaboration between industry stakeholders and policymakers.
RiskThe delayed launch of life-saving treatments in Europe poses a significant risk to public health, highlighting the need for policymakers to balance trade interests with the need for timely access to essential medicines.